CN116270836A - External pharmaceutical composition for treating leukoplakia vulvae - Google Patents
External pharmaceutical composition for treating leukoplakia vulvae Download PDFInfo
- Publication number
- CN116270836A CN116270836A CN202310329868.5A CN202310329868A CN116270836A CN 116270836 A CN116270836 A CN 116270836A CN 202310329868 A CN202310329868 A CN 202310329868A CN 116270836 A CN116270836 A CN 116270836A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- borneol
- leukoplakia vulvae
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002741 leukoplakia Diseases 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940116229 borneol Drugs 0.000 claims abstract description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 19
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 9
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 9
- 241000208368 Euonymus alatus Species 0.000 claims abstract description 9
- 241001071917 Lithospermum Species 0.000 claims abstract description 8
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 238000002156 mixing Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 240000003152 Rhus chinensis Species 0.000 claims description 4
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 4
- 241000213006 Angelica dahurica Species 0.000 claims description 3
- 241000972673 Phellodendron amurense Species 0.000 claims description 3
- 240000001341 Reynoutria japonica Species 0.000 claims description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 230000036407 pain Effects 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 14
- 208000003251 Pruritus Diseases 0.000 abstract description 13
- 230000008961 swelling Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 241000238631 Hexapoda Species 0.000 abstract description 2
- 230000036560 skin regeneration Effects 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 239000002674 ointment Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 5
- 210000003905 vulva Anatomy 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000006669 vulvar dystrophy Diseases 0.000 description 1
- 208000037897 vulvar eczema Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses an external pharmaceutical composition for treating leukoplakia vulvae, which relates to the technical field of external pharmaceutical compositions and comprises the following components in parts by weight: 40-55 parts of polygonum multiflorum, 40-50 parts of radix sophorae flavescentis, 35-45 parts of safflower, 30-35 parts of gallnut, 17-23 parts of radix angelicae, 14-20 parts of euonymus alatus, 10-15 parts of cortex phellodendri, 10-15 parts of lithospermum and 3-10 parts of borneol. The invention can directly act on focus parts, has good treatment effect, small side effect on the whole body, safe use, has the effects of clearing heat and removing dampness, promoting blood circulation and relieving itching, reducing swelling and pain, dispelling wind and killing insects, reduces discomfort at focus parts and promotes skin regeneration.
Description
Technical Field
The invention relates to the technical field of external pharmaceutical compositions, in particular to an external pharmaceutical composition for treating leukoplakia vulvae.
Background
White lesions of the vulva are also called white lesions of the vulva, vulvar dystrophy and the like, and are commonly called various female yin diseases, and the common diseases include sclerotic atrophic moss, vulvar dermatitis, atypical hyperplasia and the like. In recent years, domestic and foreign practices prove that most of vulvar white lesions are inflammatory, and the cancer transformation rate is only 2-5%. At present, it is claimed that, except for a few surgical treatments, active non-surgical treatments should be applied to white lesions caused by various chronic inflammatory or proliferative and atrophic lesions.
Symptoms: subjective symptoms such as pudendum itch and pudendum pain, white vulva, harder skin and thickened, and chapping, atrophy and the like; pathogenesis is that: white lesions of the vulva belong to the categories of pruritus vulvae, yin erosion, yin swelling and the like in traditional Chinese medicine, and ancient people think that the white lesions are mostly caused by spleen deficiency and dampness-resolving, liver Yu Shengre and damp-heat downward pouring.
A topical pharmaceutical composition for treating leukoplakia vulvae is provided for treating symptoms and pathogenesis.
Disclosure of Invention
The invention aims at: the invention provides an external pharmaceutical composition for treating leukoplakia vulvae, which can directly act on focus parts, has good treatment effect and small side effect on the whole body and is safe to use.
The invention adopts the following technical scheme for realizing the purposes:
a topical pharmaceutical composition for treating leukoplakia vulvae comprises the following components in parts by weight:
40-55 parts of polygonum multiflorum, 40-50 parts of radix sophorae flavescentis, 35-45 parts of safflower, 30-35 parts of gallnut, 17-23 parts of radix angelicae, 14-20 parts of euonymus alatus, 10-15 parts of cortex phellodendri, 10-15 parts of lithospermum and 3-10 parts of borneol.
Further, 47 parts of polygonum multiflorum, 45 parts of radix sophorae flavescentis, 40 parts of safflower, 32 parts of Chinese gall, 20 parts of radix angelicae, 17 parts of euonymus alatus, 12 parts of phellodendron, 12 parts of lithospermum and 6 parts of borneol.
Further, it is a liquid, gel or paste.
A preparation method of an external pharmaceutical composition for treating leukoplakia vulvae comprises the following steps:
removing impurities from the rest eight medicinal materials except borneol, cleaning, drying, pulverizing into coarse powder, and uniformly mixing;
step (2), placing the obtained coarse powder into a heating container, adding 65% ethanol for soaking, controlling the temperature to be 40-60 ℃, heating for 3-5 hours, and filtering to obtain a soaking solution;
and (3) adding a small amount of 95% ethanol into borneol for many times, grinding until the ethanol is completely dissolved, adding the obtained solution into the prepared impregnating solution, and stirring uniformly to obtain the pharmaceutical composition.
Further, recovering ethanol in the obtained external pharmaceutical composition by a single-effect vacuum pressure-reducing concentrator, and concentrating the extract to 1.1-1.3g/mL to obtain the external pharmaceutical composition thick paste.
Further, adding antioxidant and surfactant into the medicinal composition, mixing to obtain liquid, and packaging the liquid medicine in a spraying device to obtain spray.
Mixing the topical medicinal composition soft extract with gel matrix carbomer or cellulose derivative or sodium alginate or carbopol, and stirring to obtain gel.
Mixing the topical medicinal composition soft extract with ointment matrix to obtain ointment.
The theoretical basis of the invention is:
polygonum multiflorum Thunb: has effects of removing toxic substances, resolving carbuncle, and preventing malaria. Is mainly used for treating sore and carbuncle, scrofula and rubella pruritus; radix Sophorae Flavescentis: has effects of clearing heat, eliminating dampness, and killing parasites. Is mainly used for treating damp-heat diarrhea, yin swelling, yin itching, eczema, skin itch and scabies; safflower: has effects of promoting blood circulation, dredging channels, removing blood stasis, and relieving pain. Is mainly used for treating traumatic injury, stasis swelling and pain, stasis macula and dark color; gallnut: has effects of astringing, stopping bleeding, eliminating dampness, and healing sore. Mainly treats the wet sore and the toxic swelling; radix Angelicae Dahuricae has effects of relieving exterior syndrome, dispelling cold, dispelling pathogenic wind, relieving pain, eliminating dampness, relieving leukorrhagia, relieving swelling, expelling pus, dispelling pathogenic wind, and relieving itching. Can be used for treating common cold due to wind-cold, headache, toothache, arthralgia, sore, carbuncle, toxic swelling, skin rheumatism, and pruritus; euonymus alatus: has repercussive, analgesic, and insecticidal effects. Is commonly used for treating the symptoms of lump, traumatic injury, joint swelling and pain, and abdominal pain due to worm accumulation; cortex Phellodendri: has effects of clearing heat, eliminating dampness, purging pathogenic fire, removing toxic substances, and removing bone steaming. Is mainly used for treating damp-heat leukorrhagia, heat stranguria and pain, damp-heat diarrhea, jaundice, damp-heat beriberi, flaccidity syndrome, bone steaming and fatigue heat, pyocutaneous disease swelling and toxin, eczema and pruritus; radix Arnebiae: has effects of clearing heat, cooling blood, promoting blood circulation, removing toxic substance and promoting eruption. Mainly treats warm diseases, blood heat and toxin exuberance, macula, purple black, measles, sore and ulcer and eczema; borneol: has effects of inducing resuscitation, refreshing mind, clearing heat and relieving pain. It is mainly used for treating the symptoms of dark and dim complexion, conjunctival congestion, swelling and pain, sore throat, sore pain, sore ulcer and ulcer without healing.
The beneficial effects of the invention are as follows:
the invention can directly act on focus parts, has good treatment effect, small side effect on the whole body, safe use, has the effects of clearing heat and removing dampness, promoting blood circulation and relieving itching, reducing swelling and pain, dispelling wind and killing insects, reduces discomfort at focus parts and promotes skin regeneration.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A topical pharmaceutical composition for treating leukoplakia vulvae comprises the following components in parts by weight: 40 parts of fleece-flower root, 40 parts of kuh-seng, 35 parts of safflower, 30 parts of Chinese gall, 17 parts of dahurian angelica root, 14 parts of euonymus alatus, 10 parts of amur corktree bark, 10 parts of lithospermum and 3 parts of borneol.
The preparation method comprises the following steps: removing impurities from the rest eight medicinal materials except borneol, cleaning, drying, pulverizing into coarse powder, and uniformly mixing; step (2), placing the obtained coarse powder into a heating container, adding 65% ethanol for soaking, controlling the temperature at 40 ℃, heating for 5 hours, and filtering to obtain a soaking solution; and (3) adding a small amount of 95% ethanol into borneol for many times, grinding until the ethanol is completely dissolved, adding the obtained solution into the prepared impregnating solution, and stirring uniformly to obtain the pharmaceutical composition.
Recovering ethanol in the obtained external pharmaceutical composition by a single-effect vacuum pressure-reducing concentrator, concentrating the extract, and concentrating the concentrate to 1.1-1.3g/mL to obtain the external pharmaceutical composition thick paste. Mixing the topical medicinal composition soft extract with gel matrix carbomer or cellulose derivative or sodium alginate or carbopol, and stirring to obtain gel.
Example 2
A topical pharmaceutical composition for treating leukoplakia vulvae comprises the following components in parts by weight: 47 parts of fleece-flower root, 45 parts of kuh-seng, 40 parts of safflower, 32 parts of Chinese gall, 20 parts of dahurian angelica root, 17 parts of euonymus alatus, 12 parts of phellodendron bark, 12 parts of lithospermum and 6 parts of borneol.
The preparation method comprises the following steps: removing impurities from the rest eight medicinal materials except borneol, cleaning, drying, pulverizing into coarse powder, and uniformly mixing; step (2), placing the obtained coarse powder into a heating container, adding 65% ethanol for soaking, controlling the temperature at 45 ℃, heating for 4 hours, and filtering to obtain a soaking solution; and (3) adding a small amount of 95% ethanol into borneol for many times, grinding until the ethanol is completely dissolved, adding the obtained solution into the prepared impregnating solution, and stirring uniformly to obtain the pharmaceutical composition.
Adding antioxidant and surfactant into the medicinal composition, mixing to obtain liquid, and packaging the liquid medicine in a spraying device to obtain spray.
Example 3
A topical pharmaceutical composition for treating leukoplakia vulvae comprises the following components in parts by weight: 40-55 parts of polygonum multiflorum, 40-50 parts of radix sophorae flavescentis, 35-45 parts of safflower, 30-35 parts of gallnut, 17-23 parts of radix angelicae, 14-20 parts of euonymus alatus, 10-15 parts of cortex phellodendri, 10-15 parts of lithospermum and 3-10 parts of borneol.
The preparation method comprises the following steps: removing impurities from the rest eight medicinal materials except borneol, cleaning, drying, pulverizing into coarse powder, and uniformly mixing; step (2), placing the obtained coarse powder into a heating container, adding 65% ethanol for soaking, controlling the temperature at 50 ℃, heating for 3 hours, and filtering to obtain a soaking solution; and (3) adding a small amount of 95% ethanol into borneol for many times, grinding until the ethanol is completely dissolved, adding the obtained solution into the prepared impregnating solution, and stirring uniformly to obtain the pharmaceutical composition.
Recovering ethanol from the obtained topical medicinal composition by single-effect vacuum concentrating device, concentrating the extractive solution to 1.1-1.3g/mL to obtain topical medicinal composition soft extract, and mixing the topical medicinal composition soft extract with ointment matrix to obtain ointment.
Observation of efficacy of treatment of leukoplakia vulvae:
the invention clinically selects 86 patients and diagnosis standard: according to subjective symptoms such as pudendum itch and pudendum pain, the vulva is white, the skin is harder and thickened, symptoms such as chapping and atrophy are produced, and lesions and living tissues are inspected, so that the leukoplakia vulvae is diagnosed.
Of 84, the treatment group was 42, and the control group was 42.
The application method comprises the following steps: the control group is divided into two groups, wherein one group is coated with other external ointments every day, and the other group is coated with other external sprays every day, and the external sprays are used according to instructions; the treatment groups were divided into two groups, one group was administered with the spray prepared in example 2 of the present invention 5 times a day; a group of ointments prepared in example 3 of the present invention were applied daily, 3 times a day, 20 times a day, and then washed, 15 days being a course of treatment.
Standard of efficacy:
and (3) curing: pudendum itch and pain disappear, local color and luster is recovered to be normal, and the skin is soft, smooth and elastic.
The effect is shown: the pudendum itch and pudendum pain basically disappear, the local color is close to normal, the keratinization hardness is obviously reduced, and the elasticity is basically recovered.
The method is effective: the pudendum itch and the pudendum pain are relieved, and the local lesions are more comfortable than the past.
Invalidation: no change in symptoms or signs.
Treatment results after 5 treatment periods:
treatment results: of the 42 treatment groups, 36 cases were cured, the cure rate was 86%,41 cases were effective, the effective rate was 98%, and 0 cases were ineffective. The result shows that the external medicine composition can treat leukoplakia vulvae.
The present invention is not limited to the preferred embodiments, but the patent protection scope of the invention is defined by the claims, and all equivalent structural changes made by the application of the present invention are included in the protection scope of the present invention.
Claims (5)
1. An external pharmaceutical composition for treating leukoplakia vulvae is characterized by comprising the following components in parts by weight: 40-55 parts of polygonum multiflorum, 40-50 parts of radix sophorae flavescentis, 35-45 parts of safflower, 30-35 parts of gallnut, 17-23 parts of radix angelicae, 14-20 parts of euonymus alatus, 10-15 parts of cortex phellodendri, 10-15 parts of lithospermum and 3-10 parts of borneol.
2. A topical pharmaceutical composition for the treatment of leukoplakia vulvae according to claim 1, characterized in that: 47 parts of fleece-flower root, 45 parts of kuh-seng, 40 parts of safflower, 32 parts of Chinese gall, 20 parts of dahurian angelica root, 17 parts of euonymus alatus, 12 parts of phellodendron bark, 12 parts of lithospermum and 6 parts of borneol.
3. A topical pharmaceutical composition for the treatment of leukoplakia vulvae according to claim 1, characterized in that: it is in the form of liquid, gel or paste.
4. The external pharmaceutical composition for treating leukoplakia vulvae according to claim 1, wherein the specific preparation steps are as follows:
removing impurities from the rest eight medicinal materials except borneol, cleaning, drying, pulverizing into coarse powder, and uniformly mixing;
step (2), placing the obtained coarse powder into a heating container, adding 65% ethanol for soaking, controlling the temperature to be 40-60 ℃, heating for 3-5 hours, and filtering to obtain a soaking solution;
and (3) adding a small amount of 95% ethanol into borneol for many times, grinding until the ethanol is completely dissolved, adding the obtained solution into the prepared impregnating solution, and stirring uniformly to obtain the pharmaceutical composition.
5. A topical pharmaceutical composition for the treatment of leukoplakia vulvae according to claim 4, wherein: recovering ethanol in the obtained topical pharmaceutical composition by a single-effect vacuum pressure-reducing concentrator, concentrating the extractive solution to 1.1-1.3g/mL, and obtaining topical pharmaceutical composition soft extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310329868.5A CN116270836A (en) | 2023-03-30 | 2023-03-30 | External pharmaceutical composition for treating leukoplakia vulvae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310329868.5A CN116270836A (en) | 2023-03-30 | 2023-03-30 | External pharmaceutical composition for treating leukoplakia vulvae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116270836A true CN116270836A (en) | 2023-06-23 |
Family
ID=86837750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310329868.5A Pending CN116270836A (en) | 2023-03-30 | 2023-03-30 | External pharmaceutical composition for treating leukoplakia vulvae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270836A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552501A (en) * | 2011-12-29 | 2012-07-11 | 王爱华 | External traditional Chinese medicine composition for treating leukoplakia vulvae |
| CN112641881A (en) * | 2020-12-24 | 2021-04-13 | 肖雁冰 | Chinese herbal medicine ointment for treating leukoplakia vulvae |
-
2023
- 2023-03-30 CN CN202310329868.5A patent/CN116270836A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552501A (en) * | 2011-12-29 | 2012-07-11 | 王爱华 | External traditional Chinese medicine composition for treating leukoplakia vulvae |
| CN112641881A (en) * | 2020-12-24 | 2021-04-13 | 肖雁冰 | Chinese herbal medicine ointment for treating leukoplakia vulvae |
Non-Patent Citations (1)
| Title |
|---|
| 张璐;王建玲;: "外阴白斑的中医药治疗近况", 湖南中医杂志, vol. 32, no. 09, pages 193 - 194 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112426390A (en) | Natural traditional Chinese medicine acne-removing composition and preparation method thereof | |
| CN111467433B (en) | A topical Chinese medicinal composition and paste for promoting wound healing, and its preparation method | |
| CN108403937A (en) | It is a kind of to treat dermopathic external traditional Chinese medicine ointment and preparation method thereof | |
| CN1915351A (en) | Composition of Chinese traditional medicine in use for treating burn and scald, and product for resolving poxes, and preparation method | |
| CN106581439A (en) | Traditional Chinese medicine composition for treating wounds, diabetic feet and skin ulceration, and preparation method thereof | |
| CN106822321B (en) | Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris | |
| CN105999105A (en) | Traditional Chinese medicine composition for treating bedsores and diabetic ulcers and preparation method thereof | |
| CN103495085B (en) | Traditional Chinese medicine preparation for treating radiodermatitis | |
| CN109260355A (en) | A kind of composition and preparation method and the application for the treatment of and improvement psoriasis | |
| CN116270836A (en) | External pharmaceutical composition for treating leukoplakia vulvae | |
| CN111544523A (en) | Traditional Chinese medicine composition for treating skin ulceration and application thereof | |
| CN111544514A (en) | A Chinese medicinal ointment for treating burn and scald, and its preparation method | |
| CN111700989B (en) | Traditional Chinese medicine composition for dispelling wind, eliminating dampness and treating tinea pedis and preparation method thereof | |
| CN110882270B (en) | Pharmaceutical composition containing silicon-based regenerative medical material and preparation method thereof | |
| CN113546120B (en) | Traditional Chinese medicine ointment for treating acne and preparation method thereof | |
| CN100337656C (en) | Medicinal composition for treating burn and scald and its preparation method | |
| CN101658583B (en) | Traditional Chinese medicine for treating cold-dampness type skin ulcer and preparation method thereof | |
| CN109364216B (en) | External application ointment with effects of promoting blood circulation and removing blood stasis | |
| CN116492424A (en) | Chinese herbal medicine ointment for treating leukoplakia vulvae | |
| CN117085097A (en) | Traditional Chinese medicine composition for preventing and treating skin chap and traditional Chinese medicine product thereof | |
| CN104971162A (en) | Ointment for treating burn and preparation method thereof | |
| CN112439020A (en) | Traditional Chinese medicine composition and tincture for treating chronic eczema and preparation method thereof | |
| CN110917340A (en) | Composition for treating dry and itching skin and skin care ointment thereof | |
| CN112870301A (en) | Scar repairing essence and preparation method and application thereof | |
| CN115006502A (en) | Product formula for treating burns and scalds and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |